www.dailypolitical.com ·
Xeris Biopharma Nasdaqxers Releases Quarterly Earnings Results
Topic context
This topic has been covered 400182 times in the last 30 days across our monitored publishers.
The full article is on the original publisher site. This page only shows the headline and a very short excerpt.
AI insight
AI-generatedXeris Biopharma's earnings beat and raised guidance indicate strong commercial execution for RECORLEV, offsetting flat Gvoke sales from Medicare policy headwinds. The company-specific revenue and margin improvement is driven by product demand, not broad sector trends. Increased R&D spending for XP-8121 signals pipeline investment. Impact is single-company/supply-chain-specific.
Signals our AI researcher identified
Extracted by our AI model from this article and related public sources — not direct quotes from the publisher.
- Xeris Biopharma reported Q1 2026 EPS of $0.01 on revenue of $83.13M, beating estimates of $79.83M.
- Net product revenue rose 43% to $82.5M; RECORLEV sales nearly doubled to $49.8M.
- Full-year revenue guidance raised to $380M–$390M.
- Gvoke sales flat at $20.8M due to Medicare policy changes.
- Phase III trials for pipeline candidate XP-8121 planned later this year.
RECORLEV's positive sentiment drives Xeris Biopharma stock up 1-2% in 48h; PHARMA_BIOTECH sector sees limited impact.
Sign in to see all sector verdicts, full thesis and counter-argument debate.
Sector impact at a glance
- PHARMA_BIOTECHshort
Related stories
finance.yahoo.com
Ncmi Q1 2026 Earnings Transcript
economictimes.indiatimes.com
Petrol Diesel Price Hike Rs 3 Per Litre India Food Inflation Retail Growth Iran War Impact Rbi Crude Oil
finance.yahoo.com
Polypid Pypd Q1 2026 Earnings
finance.yahoo.com
Transcript Valneva Q1 2026 Earnings
fool.com